Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
Portfolio Pulse from Vandana Singh
Pfizer Inc (NYSE:PFE) and Valneva SE (NASDAQ:VALN) announced the completion of the primary vaccination series in their Phase 3 VALOR trial for the Lyme disease vaccine candidate VLA15. Participants will be monitored until the end of the Lyme disease season in 2025, with plans to submit marketing applications in 2026. The vaccine has shown a favorable safety profile, and no safety concerns have been observed by the Data Safety Monitoring Board.
July 18, 2024 | 6:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer announced the completion of the primary vaccination series in the Phase 3 trial for its Lyme disease vaccine candidate VLA15. The company plans to submit marketing applications in 2026.
The completion of the primary vaccination series in the Phase 3 trial is a significant milestone for Pfizer. The positive safety profile and the plan to submit marketing applications in 2026 are likely to boost investor confidence.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Valneva, in collaboration with Pfizer, completed the primary vaccination series in the Phase 3 trial for the Lyme disease vaccine candidate VLA15. The company plans to submit marketing applications in 2026.
The completion of the primary vaccination series in the Phase 3 trial is a significant milestone for Valneva. The positive safety profile and the plan to submit marketing applications in 2026 are likely to boost investor confidence.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80